TRCT
FMTX

Tower Research Capital (TRC)’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,680
Closed -$133K – 6914
2022
Q3 		$133K Buy
6,680
+5,169
+342% +$68.2K ﹤0.01% 2298
2022
Q2 		$10K Sell
1,511
-1,588
-51% -$11.1K ﹤0.01% 4525
2022
Q1 		$29K Buy
3,099
+1,684
+119% +$17.9K ﹤0.01% 3210
2021
Q4 		$20K Sell
1,415
-2,121
-60% -$36.7K ﹤0.01% 3701
2021
Q3 		$82K Buy
3,536
+1,173
+50% +$27.7K ﹤0.01% 2574
2021
Q2 		$59K Sell
2,363
-1,876
-44% -$50.4K ﹤0.01% 2896
2021
Q1 		$118K Buy
4,239
+3,671
+646% +$132K ﹤0.01% 2477
2020
Q4 		$20K Sell
568
-2,237
-80% -$97.4K ﹤0.01% 3891
2020
Q3 		$140K Buy
2,805
+2,609
+1,331% +$105K ﹤0.01% 2880
2020
Q2 		$9K Buy
+196
New +$8.5K ﹤0.01% 4079

Tower Research Capital (TRC)'s FMTX Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 6,680 shares — an estimated $133K sold.

Tower Research Capital (TRC) first reported a position in FMTX in Q2 2020 and held it in 10 quarters. The position peaked at $140K in Q3 2020. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

  • Tower Research Capital (TRC) reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 6,680 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $133K.
  • Tower Research Capital (TRC) first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Forma Therapeutics Holdings, Inc. Common Stock position peaked at $140K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.